Story perspectives

Novo Nordisk Boosts 2025 Outlook on Wegovy, Ozempic Surge

5/17/2026

Summary

Story summary

Novo Nordisk raised its 2025 outlook on 01/30/2025, citing stronger Wegovy and Ozempic demand.
GLP-1 diabetes sales generated DKK 270 billion in 2024, while obesity-care revenue doubled, driven by Wegovy and expanded production in Europe and North America.
The company announced multibillion-dollar investments in Denmark and the United States during 2024-early 2025 to boost GLP-1 output.
Novo Nordisk reiterated plans for dividends and share buybacks in a 02/06/2025 presentation.

1 of 1

Story summary

Novo Nordisk raised its 2025 outlook on 01/30/2025, citing stronger Wegovy and Ozempic demand.
GLP-1 diabetes sales generated DKK 270 billion in 2024, while obesity-care revenue doubled, driven by Wegovy and expanded production in Europe and North America.
The company announced multibillion-dollar investments in Denmark and the United States during 2024-early 2025 to boost GLP-1 output.
Novo Nordisk reiterated plans for dividends and share buybacks in a 02/06/2025 presentation.